ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1529

Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients

Noha Elemam1, Mahmood Hachim2, Suad Hannawi3 and Azzam Maghazachi4, 1University of Sharjah, Sharjah, United Arab Emirates, 2Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, 3Ministry of Health and Prevention, Dubai, United Arab Emirates, 4University of Sharjah, Sharjah

Meeting: ACR Convergence 2020

Keywords: Biomarkers, chemokines, cytokines, Gene Expression, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells, and T cells. Additionally, soluble mediators aid in the interaction between immune and non-immune cells. Cytokines are soluble mediators that play a crucial role in the inflammatory processes that could lead to joint destruction associated with RA, while chemokines play a major role in the migration of various cell types into inflammatory sites in RA (Brennan and McInnes 2008, Szekanecz, Vegvari, et al. 2010, Elemam, Hannawi, et al. 2020). In this study, we aimed at exploring chemokines and cytokines that could possibly be used to aid in evaluating the differences between healthy controls and RA patients.

Methods: Publicly available transcriptome dataset (GSE64708) of peripheral blood mononuclear cells (PBMCs) of RA patients and healthy controls were analyzed using the GEO2R tool. Then, the cytokines and chemokines were selected from the top 250 significant genes. Whole blood samples were collected from the recruited 17 RA patients (satisfying the 2010 ACR/EULAR classification criteria for RA) and 16 healthy controls (with no diagnosis of autoimmune diseases). Then, blood was separated to obtain PBMCs using the Ficoll density gradient method. RNA was extracted and gene expression was assessed using qRT-PCR. Statistical analysis was done using the unpaired t-test or Mann-Whitney test, after the assessment of data distribution. P-value < 0.05 was considered statistically significant.

Results: In silico analysis showed that several chemokines, cytokines, and innate receptors such as toll-like receptors were differentially expressed between RA patients and healthy controls. Hence, some of these cytokine and chemokine ligands and receptors were validated and assessed in PBMCs of RA patients and healthy controls. Regarding the chemokines, CCR4, CCL2, CKLF, and CXCL10 were found to be upregulated in RA patients (Figure 1). Similarly, the proinflammatory chemokine IL-1β, IL-1 receptor antagonist (IL1RN) as well as the cytokine receptor component IL12RB2 exhibited an upregulation in the PBMCs of RA patients while the T helper 1 cytokine IFN-γ did not display any differential expression in PBMCs of RA patients. Furthermore, the innate toll-like receptors TLR3 and TLR10 were upregulated in PBMCs of RA patients.

Conclusion: In conclusion, certain chemokines and cytokines seem to play a major role in the pathogenesis of RA disease. Gene expression of these molecules; CCR4, CCL2, CKLF, CXCL10, IL-1β, IL-1RN, IL12RB2, TLR3, and TLR10 in PBMCs could be used as promising biomarkers for RA disease.

Figure 1. Assessment of gene expression of chemokines, cytokines, and toll-like receptors in the PBMCs of RA patients and healthy controls.


Disclosure: N. Elemam, None; M. Hachim, None; S. Hannawi, None; A. Maghazachi, None.

To cite this abstract in AMA style:

Elemam N, Hachim M, Hannawi S, Maghazachi A. Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/differentially-expressed-chemokines-and-cytokines-in-peripheral-blood-mononuclear-cells-pbmcs-of-rheumatoid-arthritis-ra-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differentially-expressed-chemokines-and-cytokines-in-peripheral-blood-mononuclear-cells-pbmcs-of-rheumatoid-arthritis-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology